The role of estrogens in men and androgens in women

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 1, 2003, Pages 195-218

  Khosla, Sundeep ^a   Bilezikian, John P ^b  

^a MAYO CLINIC   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; ANTIESTROGEN; AROMATASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; OSTEOCALCIN; PRASTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANIMAL CELL; ANIMAL MODEL; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME DEFICIENCY; FEMALE; HORMONE ACTION; HUMAN; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; REVIEW; SKELETON;

ANIMALIA;

EID: 0037300446     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00087-7     Document Type: Review

References (92)

1. Riggs BL, Khosla S, Melton III LJ, A unitary model for involutional osteoporosis: estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73.
2. Khosla S, Melton III LJ, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002;87:1443-50.
3. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-61.
4. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-98.
5. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-5.
6. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599-603.
7. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104:1-20.
8. Weihua Z, Makela S, Andersson LC, et al. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001;98:6330-5.
9. Deladoey J, Fluck C, Bex M, et al. Aromatase deficiency caused by a novel P450 arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 1999;84:4050-4.
10. Simpson ER, Zhao Y, Agarwal VR, et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-214.
11. Bilezikian JP, Khosla S, Riggs BL. Estrogen effects on bone in the male skeleton. In Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology, San Diego: Academic Press; 2002. p. 1467-76.
12. Hemsell DL, Edman CD, Marks JF, et al. Massive extraglandular aromatization of plasma androstenedione resulting in feminization of a prepubertal boy. J Clin Invest 1977;60:455-64.
13. Bulun SE, Noble LS, Takayama K, et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1999;61:133-9.
14. Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998;83:1348-57.
15. Shozu M, Takayam K, Bulun SE. Mutation in 5′-flanking region of CYP19 gene causes excessive peripheral aromatase expression in boy with gynecomastia. Proceedings of the 80th Annual Meeting of the Endocrine Society, New Orleans LA, 1998.
16. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999;84:4677-94.
17. Zachmann M, Prader A, Sobel EH, et al. Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogen in pubertal growth of girls. J Pediat 1986;108:694-7.
18. Coen P, Kulin H, Ballantine T, et al. An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. N Engl J Med 1991;324:317-22.
19. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-55.
20. Grumbach MM, Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Textbook of Endocrinology. 3rd edition. Philadelphia: WB Saunders; 1998, p. 1509-1625.
21. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us. Endocr Rev 1999;20:358-417.
22. Windahl SH, Hollberg K, Vidal O, et al. Female estrogen receptor B-/-mice are partially protected against age-related trabecular bone loss. J Bone Min Res 2001;16:1388-98.
23. Oz OK, Zerwekh JE, Fisher C, et al. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res 2000;15:507-14.
24. Bilezikian JP, Sex steroids, mice and men: when androgens and estrogens get very close to each other. J Bone Miner Res 2002;17:563-6.
25. Lubahn DB, Moyer JS, Golding TS, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11162-6.
26. Korach KS, Couse JF, Curtis SW, et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 1996;51:159-86.
27. -/- mice. J Clin Invest 1999;104:895-901.
28. Vidal O, Lindberg MK, Hollberg K, et al. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA 2000;97:5474-9.
29. Denger S, Reid G, Kos M, et al. ER alpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 2001;15:2064-77.
30. Gentile MA, Zhang H, Harada S, et al. Bone response to estrogen replacement in OVX double estrogen receptor-(alpha and beta) knockout mice. J Bone Min Res 2001;16(Suppl I): S146.
31. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-β in bone remodeling in females but not in males. Bone 2002;30:18-25.
32. Lindberg MK, Moverare SE, Skrtic S, et al. Two different pathways for maintenance of trabecular bone in adult mice. J Bone Miner Res 2002;17:555-62.
33. Ke HZ, Chidsey-Frink KL, Qi H, et al. The role of estrogen receptor-β (ER-β) in the early age-related bone gain and later age-related bone loss. J Bone Miner Res 2001;16(Suppl I): S160.
34. Fisher CR, Graves KH, Parlow AF, et al. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998;95:6965-70.
35. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997;100:1755-9.
36. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res 1997;12:1833-43.
37. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74.
38. Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999;84:3626-35.
39. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol 1998;49:803-9.
40. Van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000;85:3276-82.
41. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000;133:951-63.
42. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001;86:192-9.
43. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555-61.
44. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000;106:1553-60.
45. Leder BZ, Schoenfeld DA, LeBlanc K, et al. Both estradiol and testosterone play fundamental roles in the maintenance of normal bone turnover in men. J Bone Miner Res 2001;16(Suppl I):S171.
46. Lian JB, Stein GS, Canalis E, et al. Bone formation: osteoblast lineage cells, growth factors, matrix proteins, and the mineralization process. In: Favus MF, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th edition. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 14-38.
47. Taxel P, Kennedy DG, Fall PM, et al. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 2001;86:2869-74.
48. Shevde NK, Bendixen AC, Dienger KM, et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829-34.
49. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κ B ligand (RANKL)-induced JNK activation. J Biol Chem 2001;276:8836-40.
50. Huber DM, Bendixen AC, Pathrose P, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001;142:3800-8.
51. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 1996;2:1132-6.
52. Chen JR, Kousteni S, Bellido T, et al. Gender-independent induction of murine osteoclast apoptosis in vitro by either estrogen or non-aromatizable androgens. J Bone Miner Res 2001;16(Suppl I):S159.
53. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.
54. Kassem M, Harris SA, Spelsberg TC, et al. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic lineage cell line with high levels of estrogen receptors. J Bone Miner Res 1996;11:193-9.
55. Bellido T, Jilka RL, Boyce BF. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. J Clin Invest 1995;95:2886-95.
56. Hofbauer LC, Ten RM, Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen- responsive human osteoblastic cell line. J Bone Miner Res 1999;14:1330-7.
57. Khosla S, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002;87:1550-4.
58. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
59. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-70.
60. Saika M, Inoue D, Kido S, et al. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 2001;142:2205-12.
61. Hofbauer LC, Hicok KC, Chen D, et al. Regulation of osteoprotegerin gene expression and protein production by androgens and anti-androgens in human osteoblastic cells. Eighty-third Annual Meeting of the Endocrine Society, 2001. p. 254-55.
62. Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001;16:2118-25.
63. Munoz-Torres M, Jodar E, Quesada M, et al. Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif Tissue Int 1995;57:94-6.
64. Soule SG, Conway G, Prelevic GM, et al. Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocrinol 1995;43:671-5.
65. Bertelloni S, Baroncelli GI, Federico G, et al. Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 1998;50:309-14.
66. Marcus R, Leary D, Schneider DL, et al. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 2000;85:1032-7.
67. Vanderschueren D, Van Herck E, Suiker AMH, et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res 1993;8:801-9.
68. Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990;8:612-7.
69. Gallagher AC, Chambers TJ, Tobias JH. Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats. Am J Physiol 1996;270: E407-12.
70. Mason RA, Morris HA. Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats. J Bone Miner Res 1997;12:1431-7.
71. Tobias JH, Gallagher A, Chambers TJ. 5α-dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol 1994;267: E853-9.
72. Coxam V, Bowman BM, Mecham M, et al. Effects of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats. Bone 1996;19:107-14.
73. Durbridge TC, Morris HA, Parsons AM, et al. Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy. Calcif Tissue Int 1990;47:383-7.
74. Turner RT, Lifrak ET, Beckner M, et al. Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol 1990;258:E673-7.
75. Lea CK, Flanagan AM. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J Endocrinol 1999;160:111-7.
76. Zborowski JV, Cauley JA, Talbott EO, et al. Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic influence in female bone. J Clin Endocrinol Metab 2000;85:3496-506.
77. Good C, Tulchinsky M, Mauger D, et al. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999;72:21-5.
78. Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 1996;97:14-21.
79. Szathmari M, Szucs J, Feher T, et al. Dehydroepiandrosteronc sulphate and bone mineral density. Osteoporos Int 1994;4:84-8.
80. Rozenberg S, Ham H, Bosson D, et al. Age, steroids and bone mineral content. Maturitas 1990;12:137-43.
81. Davidson BJ, Riggs BL, Wahner HW, et al. Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures. Obstet Gynecol 1983;61:275-8.
82. Barrett-Connor E, Kritz-Silverstein D, Edelstein SL. A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am J Epidemiol 1993;137:201-6.
83. Devogelaer JP, Crabbe J, De Deuxchaisnes CN. Bone mineral density in Addison's discase: evidence for an effect of adrenal androgens on bone mass. BMJ 1987;294:798-800.
84. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
85. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-37.
86. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82:3498-505.
87. Chesnut III CH, Nelp WB, Baylink DJ, et al. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977;26:267-77.
88. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986;1:347-57.
89. Hassager C, Podenphant J, Riis BJ, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal women. Metabolism 1989;38:238-42.
90. Need AG, Horowitz M, Walker CJ, et al. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis. Bone 1989;10:3-6.
91. Johansen JS, Hassager C, Podenphant J, et al. Treatment of postmenopausal osteoporosis. Is the anabolic steroid nandrolone decanoate a candidate? Bone Miner 1989;6:77-86.
92. Gennari C, AgnusDei D, Gonnelli S, et al. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study. Maturitas 1989;11:187-97.